XTX Topco Ltd Sells 70,383 Shares of Cerus Corporation (NASDAQ:CERS)

XTX Topco Ltd decreased its holdings in shares of Cerus Corporation (NASDAQ:CERS) by 26.7% in the first quarter, HoldingsChannel reports. The firm owned 192,771 shares of the biotechnology company’s stock after selling 70,383 shares during the quarter. XTX Topco Ltd’s holdings in Cerus were worth $268,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of CERS. Wealth Enhancement Advisory Services LLC bought a new position in Cerus during the 4th quarter valued at approximately $25,000. Merit Financial Group LLC bought a new position in shares of Cerus in the 1st quarter worth approximately $25,000. Dark Forest Capital Management LP bought a new position in shares of Cerus in the 4th quarter worth approximately $34,000. Pallas Capital Advisors LLC bought a new position in shares of Cerus in the 1st quarter worth approximately $37,000. Finally, Ameriprise Financial Inc. bought a new position in shares of Cerus in the 4th quarter worth approximately $40,000. Institutional investors own 78.37% of the company’s stock.

Cerus Stock Up 2.9%

Shares of NASDAQ:CERS opened at $1.25 on Tuesday. Cerus Corporation has a 52-week low of $1.12 and a 52-week high of $2.39. The firm has a market capitalization of $238.67 million, a P/E ratio of -12.45 and a beta of 1.55. The stock has a 50 day moving average price of $1.39 and a 200-day moving average price of $1.45. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.35 and a current ratio of 2.00.

Cerus (NASDAQ:CERS) last announced its earnings results on Tuesday, August 5th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%. The firm had revenue of $60.10 million during the quarter, compared to the consensus estimate of $51.80 million. As a group, equities research analysts anticipate that Cerus Corporation will post -0.08 EPS for the current fiscal year.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.